FDA Issues Warning On Voltaren Gel Liver Risks

Law360, New York (December 7, 2009, 4:46 PM EST) -- The U.S. Food and Drug Administration has issued a warning to health care professionals that Novartis AG and Endo Pharmaceuticals Inc.'s topical pain reliever Voltaren Gel carries a risk of potentially fatal liver damage, including organ failure.

Prescribing information for Voltaren Gel has been updated to include new warnings and precautions about the potential for elevation in liver function tests during treatment with all products containing diclofenac sodium, the FDA said Friday.

Voltaren Gel — a trade name for diclofenac sodium gel — is a nonsteroidal...
To view the full article, register now.